Magnetically-driven innovative solution developed for personalized intracranial tumor therapy

Brain tumors remain among the most challenging conditions in modern medicine. Due to their complexity and location, many of them are difficult to access, even with the most advanced surgical and therapeutic approaches. Although significant progress has been made in radiotherapy, chemotherapy, and surgical techniques, certain tumors—especially those near critical brain structures—still present considerable risks.

In a study published in Nature Biomedical Engineering, a research team led by Prof. XU Tiantian from the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, along with collaborators, developed magnetically driven biohybrid blood hydrogel fibers (BBHFs) capable of delivering chemotherapy directly to brain tumors while effectively evading the body's immune defenses. The BBHF can be a minimally invasive, highly controlled alternative.

Inspired by morphology and kinematic characteristics of the natural nematode, such as Caenorhabditis elegans, the researchers developed the BBHF (diameter is 1 mm) by in situ gelationare, combining magnetic particles with the patient's own blood, followed by the magnetization for the orientation. These BBHFs exhibited exceptional capability to evade immune cell recognition during intracranial delivery while offering real-time tracking capabilities through X-ray fluoroscopic imaging.

"The BBHFs exhibit notable characteristics of elasticity and softness, enabling them to navigate intricate environments with adaptability. It has an elastic modulus of about 100 kPa—softer than the gut, but stronger and more durable than cartilage, underscoring the exceptional softness of the BBHFs," said Prof. XU. Importantly, she pointed out that the BBHFs can traverse narrow passageways, even those with diameters smaller than their own.

By mimicking the slender morphology and adaptive undulatory movement mechanism of nematodes, the researchers achieved the precise control of the BBHF using an externally programmable magnetic field, enabling it to perform various biomimetic motion patterns such as swaying, crawling, and rolling. Experiments showed that the BBHF was able to move through the porcine cerebral cortex with gullies and arrive at the target location without leaving scratches on the soft surface.

The integration of a magnetic field unit with X-ray fluoroscopic imaging enabled the precise and real-time tracking of the BBHFs during targeted intracranial delivery, specifically directed towards tumor sites within the skull. Upon reaching their target, these BBHFs could undergo rapid splitting triggered by a high-strength magnetic field, facilitating the efficient release of therapeutic agents for effective brain tumor inhibition.  

In laboratory tests, the researchers encapsulated doxorubicin—a first-line chemotherapy—into BBHFs and used a high-strength magnetic field to trigger targeted drug release at tumor sites. The fibers remained stable until actuation, ensuring precise delivery with minimal off-target effects. Further trials in pig models showed that BBHFs can navigate through cerebrospinal fluid and deliver drugs effectively within the brain.

Furthermore, comprehensive toxicity assessments showed that the magnetic particles in BBHFs did not accumulate in vital organs such as the heart, liver, spleen, lungs and kidneys, highlighting the long-term safety of the system. Histological analysis confirmed robust tumor inhibition by BBHFs without triggering significant immune responses or tissue damage, demonstrating the therapeutic efficacy.

BBHFs represent a significant step forward in the development of personalized, minimally invasive neurosurgical techniques. By combining patient-derived materials with soft-robotic design and magnetic guidance, this innovative approach holds promise for transforming the treatments of hard-to-reach brain tumors and other central nervous system disorders.